The global allergy diagnostics market size is expected to grow USD 7.13 billion in 2026, and is projected to reach around USD 18.18 billion by 2035. The market is expanding at a CAGR of 10.96% between 2026 and 2035.
The allergy diagnostics market is primarily driven by growing research and development activities and the rising prevalence of allergic diseases. Government organizations encourage the general public to screen and diagnose allergic conditions early. Healthcare organizations provide comprehensive and high-quality allergic testing to patients. Integrating artificial intelligence (AI) into allergy diagnostics enhances the efficiency and accuracy of diagnosis. The future looks promising, with advances in diagnostics and point-of-care diagnostics.
The allergy diagnostics market refers to tests, instruments, reagents and services used to detect, quantify and characterize allergic sensitization and clinical allergy including skin testing (SPT, intradermal, patch), in vitro specific IgE assays, component-resolved/molecular diagnostics, provocation tests, multiplex panels, point-of-care allergy tests, software for reporting/interpretation, and allied lab/consulting services across clinical allergy, pulmonology, ENT devices, pediatrics and primary care.
Allergy diagnostics refers to the use of laboratory and clinical tests, including skin prick tests, specific IgE blood tests, patch tests, and molecular diagnostics, to accurately identify allergens responsible for allergic reactions and support personalized treatment decisions. The allergy diagnostics market is expanding due to the increasing global burden of food, respiratory, and drug allergies, coupled with growing awareness of early detection and preventive healthcare. A key trend is the adoption of component-resolved diagnostics and multiplex testing platforms that improve diagnostic accuracy. Technological advancements such as AI-assisted interpretation, automated laboratory analyzers, and digital diagnostic solutions are enhancing efficiency and clinical outcomes. Future opportunities are emerging through point-of-care testing, home-based allergy testing kits, and precision medicine approaches tailored to individual immune profiles. Supportive healthcare investments, expanding diagnostic infrastructure, and continuous innovation are further accelerating market growth.
The allergy diagnostics market is influenced by both internal and external factors. Internal factors include continuous technological innovation, diagnostic accuracy, product quality, expanding test portfolios, laboratory automation, skilled healthcare professionals, and strategic collaborations among diagnostic companies, all of which strengthen market competitiveness. External factors include the rising prevalence of allergic diseases, increasing environmental pollution, climate change, urbanization, favorable healthcare reimbursement in developed countries, and growing public awareness of allergy testing. Government initiatives promoting early disease detection and improved healthcare infrastructure also support market expansion. However, high diagnostic costs, limited access to advanced testing in low-income regions, shortages of trained allergy specialists, and stringent regulatory approval requirements may restrain market growth despite increasing demand for precise and personalized allergy diagnosis.
AI is reshaping allergy and immunology by integrating cutting-edge technologies to enhance patient outcomes. AI and machine learning (ML) algorithms can detect vast amounts of data and predict potential allergic reactions based on their severity. They can enable a deeper understanding of allergic diseases, enhancing accuracy and precision. Integrating AI introduces automation in diagnostics, resulting in faster results. Automated diagnostics allow healthcare professionals to provide personalized treatment to patients. AI-based wearable devices can continuously monitor health indicators in patients with chronic allergies.
Driver
Increasing Allergy Prevalence
The major growth factor for the allergy diagnostics market is the increasing prevalence of allergic reactions. Allergies are mainly caused by airborne allergens (pollens, dust mites, and molds), food allergens (peanuts, milk, and fish), and certain medications (penicillin). The different forms of allergies include allergic rhinitis, asthma, food allergy, anaphylaxis, headaches, food allergy, recurring bronchitis, and shortness of breath. The Asthma and Allergy Foundation of America (AAFA) estimated that more than 100 million people experience allergic conditions in the U.S. annually. Allergies negatively impact a person’s quality of life, affecting their sleep and mood.
Restraint
Adverse Effects and High Cost
Skin tests are more prone to side effects, such as red, itchy skin in test areas. In rare cases, an allergy skin test may cause anaphylaxis shock. Additionally, skin tests are not feasible in cases of existing skin diseases. On the other hand, in vitro tests are comparatively more costly than skin tests. This limits the affordability of several people from low- and middle-income countries.
Opportunity
What is the Future of the Allergy Diagnostics Market?
| Table | Scope |
| Market Size in 2026 | USD 6.42 Billion |
| Projected Market Size in 2035 | USD 16.45 Billion |
| CAGR (2026 - 2035) | 10.96% |
| Leading Region | North America |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Test Methodology/Assay Type, By Platform/Technology, By Specimen Type, By Setting/End-User, By Region |
| Top Key Players | Thermo Fisher Scientific, Siemens Healthineers, Roche Diagnostics, Abbott Laboratories, Beckman Coulter, bioMérieux, ALK-Abelló, Stallergenes Greer/Greer Laboratories, Omega Diagnostics, HYCOR Biomedical, LETI/HAL Allergy, Quest Diagnostics, LabCorp, Eurofins |
Which Test Methodology/Assay Type Segment Dominated the Allergy Diagnostics Market?
By test methodology/assay type, the skin prick tests segment held a dominant presence in the market by 30% in 2025. This is due to the safety of skin prick tests in both adults and children. Skin prick tests are generally performed to assess hay fever, allergic asthma, dermatitis, food allergies, penicillin allergy, and insect allergy. They are used for a wide range of purposes, allowing healthcare professionals to check for immediate allergic reactions to up to 50 different substances. They are preferred due to their rapid results and cost-effectiveness.
By test methodology/assay type, the multiplex/microarray IgE panels (component-resolved) segment is expected to grow at the fastest CAGR in the market during the forecast period. The demand for IgE-based diagnostics is increasing with its ability to detect multiple allergens. Numerous tests are available that can measure individual, highly purified allergen components, which are referred to as component-resolved diagnostics. Advancements in molecular diagnostics enable professionals to diagnose allergies using multiplex bead-based platforms.
| Segment | Share 2025 (%) |
| Automated Immunoassay Analyzers (Chemiluminescence / ELISA) | 35% |
| Lateral-flow/Rapid POC sIgE Tests | 25% |
| Multiplex Microarrays (Biochip) | 10% |
| Lab-developed Assays/LDTs | 10% |
| Digital Reporting & Interpretation Platforms (Software) | 20% |
Why Did the Automated Immunoassay Analyzers Segment Dominate the Allergy Diagnostics Market?
By platform/technology, the automated immunoassay analyzers segment held the largest revenue share of the market by 35% in 2025. This segment dominated because automated immunoassay analyzers enhance laboratory efficiency, increase throughput, and reduce manual errors. Immunoassay analyzers use an antibody as a reagent to detect and identify specific substances in a sample. They can process a large number of samples in a short period, decreasing turnaround time. They also provide consistent results.
By platform/technology, the lateral flow/rapid PoC sIgE tests segment is expected to grow with the highest CAGR in the market during the studied years. Lateral flow or PoC tests offer rapid and sensitive results for different allergy types. They enable patients to measure allergen components from the bedside or at home. Thermo Fisher Scientific’s specific IgE point-of-care can identify 92 to 95% of symptomatic patients sensitized to any allergens. Lateral flow or PoC tests can enable qualitative and semi-quantitative measurement of allergens.
How the Venous Serum/Plasma Segment Dominated the Allergy Diagnostics Market?
By specimen type, the venous serum/plasma segment contributed the biggest revenue share of the market by 45% in 2025. Venous serum/plasma is primarily used as a specimen, due to the presence of IgE antibodies specific for whole allergen extracts and individual allergen components. Patients do not need to stop treatment with medicines used to treat allergies when serum is collected, as medicines do not interact with the test. The availability of the ELISA assay procedure improves the specificity of serum tests.
By specimen type, the capillary whole blood (fingerstick PoC) segment is expected to expand rapidly in the market in the coming years. The collection of capillary whole blood involves a non-invasive method for testing allergens. It eliminates the need for a skilled professional to collect blood and also enables patients to withdraw their own blood samples. The high feasibility and cost-effectiveness of collecting capillary whole blood boost the segment’s growth.
Which Setting/End-User Segment Led the Allergy Diagnostics Market?
By setting/end-user, the allergy/immunology specialist clinics segment led the market by 40% in 2025. The segmental growth is attributed to the presence of a favorable infrastructure and suitable capital investment. This enables clinics to adopt advanced technological products for allergy detection. They possess skilled professionals to provide tailored care and treatment based on diagnostic results.
By setting/end-user, the primary care/pediatric clinics (PoC screening) segment is expected to witness the fastest growth in the market over the forecast period. The increasing number of patients in primary care for diagnosing allergies augments the segment’s growth. This is due to the increased accessibility to primary care clinics. Pediatric clinics have suitable equipment for diagnosing and treating various conditions of pediatric patients.
North America dominated the market in 2025. The availability of a robust healthcare infrastructure, the rising prevalence of allergies, and the presence of key players are the major growth factors of the market in 2024. Government organizations support the development of allergy diagnostics through funding. Research institutions in North America have state-of-the-art research and development facilities for the development of allergy diagnostics.
U.S. Market Trends
Key players, such as Thermo Fisher Scientific, Danaher Corporation, and Hycor Biomedical, deliver innovative allergy diagnostics in the U.S. The Food and Drug Administration (FDA) regulates the approval of diagnostics and allergen extracts. As of 2024, the U.S. FDA has approved a total of 19 allergen extracts.
Canada Market Trends
Asthma Canada reported that 1 in 5 Canadians suffers from respiratory allergies annually. The Food Allergy Canada’s National Food Allergy Action Plan (NFAAP) helps Canadians with food allergies with its prevention, diagnosis, and treatment. The federal government invested $4.5 million over 2 years for the NFAAP.
Asia-Pacific is expected to grow at the fastest CAGR in the allergy diagnostics market during the forecast period. The increasing patient population and the rising healthcare expenditure propel the market. People are becoming aware of the early diagnosis of allergic diseases and identifying potential allergens. The rising adoption of advanced technologies and the growing demand for PoC diagnostics foster market growth.
China Market Trends
Allergic diseases are estimated to affect around 40% of the Chinese population. Healthcare expenditure in China facilitates the use of advanced technologies for allergies. It is estimated that healthcare expenditure will reach RMB 205 trillion by 2030. China is also emerging as a global hub for clinical trials, surpassing the U.S. and Europe.
India Market Trends
In India, about 22% of adolescents are estimated to have allergic rhinitis. India’s health spending rose to Rs 6.1 lakh crore in 2024-25, an increase from Rs 3.2 lakh crore in 2020-21, accounting for 3.8% of the GDP. Alcit India Pvt. Ltd., AllVac Pharmaceuticals, and Asian Diagnostics are the major providers of allergy diagnostics in India.
Europe is registering a notable growth in the allergy diagnostics market. This expansion is mainly driven by estimates from the European Academy of Allergy and Clinical Immunology (EAACI) that nearly 150 million Europeans face chronic allergic conditions, spurring demand for routine screening. However, a rise in urbanization, industrial pollution, and changing lifestyles is resulting in higher cases of respiratory & food allergies. Key breakthroughs by European companies are emphasizing multiplex assays to study extensive panels of allergen sensitivities from small blood sample volumes.
Germany Market Trends
Novelty across the allergy diagnostics industry is propelled by rapid adoption of CRD and multiplex assays, enabling clinicians to address exact immunoglobulin E (IgE) sensitization profiles instead of expansive allergen groups. Many German laboratories are focusing on the unification of AI and data analytics to simplify intricate IgE data interpretation and electronic health record coordination.
UK Market Trends
UK’s significant expansion in the allergy diagnostics market is primarily fueled by the development of national frameworks, such as the involvement of the British Society for Allergy and Clinical Immunology (BSACI), Allergy UK, and Anaphylaxis UK, which uncovered a crisis affecting roughly 25% of the UK population. Nowadays, some national efforts are aiming at critical diagnostic delays, uncertainty in regional care standards, and the historical limitation of baseline allergy training for general practitioners (GPs).
The market in the Middle East and Africa is expected to witness significant growth in the upcoming years. This will be driven by ongoing government and private initiatives and investment in healthcare infrastructure, specifically in Saudi Arabia, the UAE, South Africa, and Egypt, to enhance access to advanced medical measures. Alongside this, the region has been promoting education among patients and healthcare providers regarding early diagnosis and preventive care, fostering overall growth.
UAE Market Trends
Recently, several assessments were released across UAE healthcare systems focusing on mapping improper penicillin allergy tags in electronic medical records to lower dependency on broad-spectrum alternatives and antimicrobial resistance. Along with this, in September 2026, the 4th annual summit anchored by the American Hospital Dubai emphasised the study of advanced multidisciplinary approaches in pediatric allergy care.
South Africa
Key breakthroughs in allergy diagnostics in South Africa are supported by an established definitive five-year national dataset (2019–2024) across seven South African cities. This further evolves biome-specific pollen calendars to directly inform clinical allergy diagnoses. Recently, the Allergy Society of South Africa hosted its flagship national conference in Cape Town in August 2026, which features specialized tracks on precision medicine, component-resolved diagnostics, and the World Allergy Training School Workshop to advance primary care practitioners.
The research activities for allergy diagnostics include the development of point-of-care diagnostics, automated devices leveraged with AI, and novel assay procedures.
Key Players: Danaher Corporation, Neogen Corporation, and Siemens Healthineers
Innovative diagnostics are tested for their safety and efficacy in clinical trials. After conducting clinical trials, regulatory agencies approve a diagnostic based on its trial data.
Key Players: Boehringer Ingelheim, MacroArray Diagnostics GmbH, and Hycor Biomedical
Patient support & services refer to providing information about different diagnostic methodologies and tailored treatments, enabling patients to manage conditions and improve their quality of life.
Javier Evelyn, Founder and CEO of Alerje, commented that the partnership with MGCC represents a significant milestone in their mission to improve the lives of millions affected by allergies. He also stated that the company is poised to deliver unprecedented advancements in allergy diagnosis and management by combining the expertise of both companies.
Strengths
Weaknesses
Opportunities
Threats
By Test Methodology/Assay Type
By Platform/Technology
By Specimen Type
By Setting/End-User
By Region
